Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
28 juin 2021 10h13 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast...
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
17 mai 2021 10h19 HE
|
Sermonix Pharmaceuticals LLC
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases in mouse models, both as monotherapy and in combination with palbociclibStudy results demonstrate...
Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer
21 avr. 2021 09h44 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic...
Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
07 janv. 2021 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
03 déc. 2020 10h20 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020
02 déc. 2020 10h25 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
13 oct. 2020 09h30 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada
30 sept. 2020 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix CEO David Portman to Participate in Women’s Health Innovation Virtual Summit
10 sept. 2020 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
08 juil. 2020 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...